Cognito Therapeutics OVERTURE trial reaches 12-month primary endpoint data lock
Summary
Cognito Therapeutics announced that the last patient in the OVERTURE Phase 3 trial has completed the 18-month treatment period and data lock for the primary 12-month endpoint analysis has been achieved. Top-line results from the primary CDR-SB endpoint will be announced in Q3 2026 following statistical analysis and regulatory review. The company reiterated its commercial readiness plan.
Why it matters
Data lock for the primary endpoint is the definitive milestone before top-line results — the next announcement will be the actual data. Cognito reiterating commercial readiness alongside the data lock signals confidence in their manufacturing and market access preparations, suggesting internal data signals are positive.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial